5409

Medico Remedies Limited Stock Price

BSE:540937 Community·₹4.2b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

540937 Share Price Performance

₹50.05
1.07 (2.18%)
₹50.05
1.07 (2.18%)
Price ₹50.05

540937 Community Narratives

There are no narratives available yet.

Recent 540937 News & Updates

Medico Remedies Limited Key Details

₹1.6b

Revenue

₹1.2b

Cost of Revenue

₹428.7m

Gross Profit

₹325.4m

Other Expenses

₹103.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 14, 2025
Earnings per share (EPS)
1.25
Gross Margin
27.07%
Net Profit Margin
6.52%
Debt/Equity Ratio
23.5%

Medico Remedies Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with proven track record.

2 Risks
1 Reward

About 540937

Founded
1994
Employees
213
CEO
Harshit Mehta
WebsiteView website
medicoremedies.com

Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.5%
  • 3 Months: -1.7%
  • 1 Year: -4.7%
  • Year to Date: 0.7%
Over the last 7 days, the market has risen 1.5%, driven by gains of 2.3% in the Financials sector. In contrast, the market has seen a decline of 4.7% over the last 12 months. Looking forward, earnings are forecast to grow by 16% annually. Market details ›